|1.90|| +0.03 / +1.60%|
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
|Geert R. Kersten||Chief Executive Officer, Treasurer & Director|
|Patricia B. Prichep||Secretary & Senior Vice President-Operations|
|Eyal Talor||Chief Scientific Officer|
|William Jones||Vice President-Quality Assurance|
|Daniel H. Zimmerman||Senior VP-Research & Cellular Immunology|